Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Goldman Sachs downgraded Alnylam Pharmaceuticals (NASDAQ:ALNY) from its previous rating to Neutral, adjusting the price target from $230.00 to $173.00. Despite the downgrade, ALNY shares have risen by 0.41% in the last 24 hours to $148.04. The new price target suggests a potential 16.86% increase from the current price. Alnylam is recognized for its pioneering work in RNA interference (RNAi) therapeutics, with five drugs on the market and several clinical programs across different therapeutic areas.
February 16, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs downgraded Alnylam Pharmaceuticals to Neutral and reduced the price target from $230.00 to $173.00, indicating a potential upside of 16.86% from the current price.
The downgrade by Goldman Sachs to a Neutral rating and the reduction in price target could have a mixed short-term impact on ALNY's stock price. While the downgrade suggests a cautious outlook, the new price target still implies a significant upside potential. Additionally, the company's strong position in RNAi therapeutics and its portfolio of marketed drugs and clinical programs may continue to support investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100